Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2013-01-24 Interim / Quarterly Rep…
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
Appendix 4C - quarterly 10 pages 51.5KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Activities Report and Appendix 4C of the ASX Listing Rules for the quarter ended 31 December 2012'. It contains detailed operational updates, financial summaries including cash flow statements, licensing and IP activities, corporate matters including management changes, and an Appendix 4C which is a quarterly report format under ASX rules. The presence of substantive financial data such as cash receipts, cash flows, and operational metrics for the quarter indicates this is a comprehensive quarterly report rather than a brief announcement or a certification. The document length (15,000 characters) and detailed content confirm it is a full quarterly report. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q2 2013
2013-01-24 English
Appendix 3B and cleansing notice 12 pages 117.7KB
Share Issue/Capital Change Classification · 100% confidence The document is an ASX announcement dated January 25, 2013, concerning a cleansing notice under section 708A of the Corporations Act 2001 (Cth). It details the exercise of 500,000 options resulting in the issuance of fully paid ordinary shares at a specified price. The document includes an Appendix 3B, which is a standard form used for new issue announcements, applications for quotation of additional securities, and agreements related to securities issuance on the ASX. The content focuses on the issuance of new shares following option exercises, compliance with relevant sections of the Corporations Act, and details about the securities issued. There is no financial performance data, management discussion, or earnings information. The document is regulatory in nature, announcing a capital change event (exercise of options and issuance of shares) and providing the required disclosures for ASX listing purposes. Therefore, the document fits the category of a Share Issue/Capital Change announcement rather than a full financial report or other categories.
2013-01-24 English
Presentation at US conference 13 pages 1.2MB
Investor Presentation Classification · 95% confidence The document is an ASX announcement dated January 7, 2013, regarding a presentation by the CEO of Genetic Technologies Limited at Cowen’s 2013 Asia Pacific Life Science Showcase. The content includes a corporate overview, product descriptions, market strategy, patent information, financial highlights, and shareholder data. It is structured as a presentation for investors and stakeholders, focusing on company strategy, products, market position, and financial summary. There are no detailed financial statements or comprehensive financial analysis typical of annual or interim reports. The document is not a transcript of a call, nor an audit or legal report. It is clearly a presentation document intended for investors and market participants. Therefore, the most appropriate classification is Investor Presentation (IP). The document length (6802 characters) supports it being a full presentation rather than a brief announcement or regulatory filing.
2013-01-06 English
Licensing update - December 2012 2 pages 110.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated December 20, 2012, providing an update on the company's non-coding DNA technology licensing program, year-to-date performance, patent re-examination status, and legal actions related to patent infringement. It is a market update focusing on licensing revenue, legal proceedings, and patent status rather than a full financial report or earnings release. The document is about business and legal updates rather than financial results or management changes. It does not contain financial statements or detailed financial analysis, nor is it a transcript or presentation. It is not a report publication announcement since it contains substantive content rather than just a notice. The content fits best under a general regulatory announcement category that covers miscellaneous filings and updates that do not fit other specific categories. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2012-12-19 English
Appointment of permanent CEO and Non-Executive Director 3 pages 40.7KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement dated December 10, 2012, regarding the appointment of a permanent CEO and a Non-Executive Director for Genetic Technologies Limited. It includes biographical details of the appointees and mentions an attached Appendix 3X Initial Director’s Interest Notice, which is a regulatory form related to director interests. The content focuses on changes in the company's board and senior management. There are no financial statements, earnings data, or other report types present. Therefore, this document fits the category of Board/Management Information (MANG).
2012-12-09 English
GTG resolves infringement claim against 454 Life Sciences 1
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated December 6, 2012, reporting the resolution of a patent infringement claim through a settlement agreement. It includes details about the parties involved, the nature of the agreement, and some background on the company. There are no financial statements, no detailed financial performance data, no regulatory certifications, or voting results. The document is a corporate announcement about a legal settlement, not a full audit report or legal proceedings update with detailed litigation status. It is not a report publication announcement since it contains substantive information about the settlement itself. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2012-12-05 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.